VIDEO: Avacincaptad pegol shows positive GA reduction, safety profile at 2 years
Click Here to Manage Email Alerts
SAN FRANCISCO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Arshad Khanani, MD, MA, FASRS, discusses 2-year results of the GATHER2 trial investigating avacincaptad pegol for geographic atrophy.
According to Khanani, patients treated with avacincaptad pegol every month saw a statistically significant decrease in GA lesion growth compared with sham, while patients dosed every other month saw comparable results.
“When we look at the absolute reduction in GA growth lesion, we see more than doubling of the treatment effect in patients treated with avacincaptad pegol, whether every month or every other month, over 2 years compared to the effect we saw at 1 year,” he said.
Khanani also discussed the safety profile of the treatment, which was well tolerated overall.
Collapse
Khanani A. Gather2: Two-year data. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Read more about
Click Here to Manage Email Alerts